Isoxazoline Derivative and Novel Process for Its Preparation
申请人:Shin Hyun Ik
公开号:US20080262032A1
公开(公告)日:2008-10-23
The present invention relates to an isoxazoline derivative having the cyclic carboxylic acid hemiketal moiety of formula (1) for use as caspase inhibitor, a process for preparing it, and a pharmaceutical composition comprising it.
METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS
申请人:Jaffe Howard S.
公开号:US20100008867A1
公开(公告)日:2010-01-14
The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-((2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
[EN] METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS<br/>[FR] PROCÉDÉ DE TRAITEMENT ET COMPOSITIONS PHARMACEUTIQUES
申请人:GILEAD SCIENCES INC
公开号:WO2010005765A1
公开(公告)日:2010-01-14
The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-((2S,3S)-2-(fIuoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran- 3-yl)-5-isopropyl-3-(isoqυinolin-1 -yl)-4,5-dihydroisoxazo!e-5-carboxamide, or a pharmaceutically acceptable salt thereof.
[EN] USE OF PHARMACEUTICAL COMPOSITIONS COMPRISING A CASPASE INHIBITOR FOR TREATING INTERSTITIAL LUNG DISEASES<br/>[FR] UTILISATION DE COMPOSITIONS PHARMACEUTIQUES RENFERMANT UN INHIBITEUR DE CASPASE POUR LE TRAITEMENT DE MALADIES PULMONAIRES INTERSTITIELLES
申请人:GILEAD SCIENCES INC
公开号:WO2010005766A1
公开(公告)日:2010-01-14
The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-(2S,3S)-2-fluoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1 -yI)-4t5-dihydroisoxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
NOVEL PROCESS FOR PREPARING 3-AMINO-5-FLUORO-4-DIALKOXYPENTANOIC ACID ESTER
申请人:Shin Hyun Ik
公开号:US20100036158A1
公开(公告)日:2010-02-11
The present invention relates to a novel process for the production of 3-amino-5-fluoro-4-dialkoxypentanoic acid ester used in the precursor of 3-amino-5-fluoro-4-oxopentanoic acid, represented by the following formula (1): wherein R1 and R2 are as defined in the Description.